RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor
cells. Giving radiation therapy in different ways may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of indium In 111 pentetreotide in treating
patients who have refractory cancer.
OBJECTIVES: I. Determine the maximum tolerated dose (MTD), toxic effects, and the
preliminary antitumor activity of indium In 111 pentetreotide.
OUTLINE: This is a dose escalation study. Patients receive indium In III pentetreotide
(OctreoScan) IV on day 1. Imaging is conducted on days 3 and 6. Treatment continues weekly
for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of at least 3 patients receive escalating doses of OctreoScan until the maximum
tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2
of 3 patients experience dose limiting toxicities. Patients are followed every 3 months for
the first year, then every 6 months thereafter.
PROJECTED ACCRUAL: Up to 35 patients will be accrued for this study.
DISEASE CHARACTERISTICS: Histologically proven malignancy with no alternate treatments
available Measurable or evaluable progressive disease Somatostatin receptors present on
tumor and uptake demonstrated on diagnostic scan with OctreoScan
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Absolute neutrophil
count at least 1,500/mm3 Hepatic: Total bilirubin no greater than 2.0 mg/dL Renal:
Creatinine clearance at least 40 mL/min Other: No active infections Not HIV positive No
coexisting medical condition Not pregnant or nursing Negative pregnancy test Fertile
patients must use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks
since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) Endocrine therapy: Not
specified Radiotherapy: At least 4 weeks since prior wide field radiation therapy Surgery:
Recovery from prior surgery